MedTrace Logo

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

NCT02185053 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2020-06-04

Study results available
· View outcomes & findings →

Summary

This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.

Conditions

Interventions

DRUG

CPC-201

Sponsors & Collaborators

  • Chase Pharmaceuticals Corporation, an affiliate of Allergan plc

    lead INDUSTRY

Principal Investigators

  • Lynn James · Allergan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02185053 on ClinicalTrials.gov